Evaluation of Use of Plastic Bags to Prevent Neonatal Hypothermia-Part III

February 18, 2019 updated by: Wally Carlo, University of Alabama at Birmingham

Randomized Evaluation of the Use of Plastic Bags to Prevent Neonatal Hypothermia in Developing Countries-Part III

The overall hypothesis is that plastic bags used in combination with WHO thermoregulation care will reduce the incidence of hypothermia in preterm/low birth weight and full term infants when compared to routine WHO thermoregulation care alone. Part III is for preterm/low birth weight infants with or without a plastic torso wrap during the first hour after birth to assist with temperature regulation during placement in an incubator.

Study Overview

Detailed Description

Incubators in the developing world often lack humidifiers. The resting dry heat increases evaporative heat loss, the most prominent form of heat loss in premature infants due to their increased body surface area and immature stratum corneum. By potentially increasing humidity around the infants and decreasing evaporative heat losses, plastic bags may improve incubator warming. This study will compare the incidence of hypothermia in infants placed in an incubator for at least one hour randomized to receive standard incubator protocol (control group) or standard incubator protocol plus a plastic bag covering their torsos and lower extremities (intervention group). The axillary temperature of each infant will be taken before placement into the incubator and one hour later when the bag will be removed. Blood pressure, blood sugar, seizures, weight gain, hyperthermia, death, observation for respiratory distress syndrome, bronchopulmonary dysplasia, pneumothorax, sepsis, intraventricular hemorrhage, periventricular leukomalacia, necrotizing enterocolitis, intestinal perforation, pulmonary hemorrhage, incubator temperature, and humidity, and length of time in an incubator will be recorded throughout the hospitalization for all infants. With an estimated baseline hypothermia rate of 90% and a hypothesized 20% absolute risk reduction (22% relative risk reduction), a sample size of 118 will be used to have a power of 80% and a confidence interval of 95%.

Study Type

Interventional

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Lusaka, Zambia
        • University Teaching Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 minute to 3 days (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Infant admitted to the NICU
  • Current weight between 1,000 and 2,500g
  • Being placed in an incubator

Exclusion Criteria:

  • Abdominal wall defect or myelomeningocele
  • Major congenital anomalies
  • Blistering skin disorder

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Sham Comparator: Incubator-no plastic bag
Placement into an incubator without a plastic bag
Infant will be placed in the incubator, wrapped in a blanket, with a cloth hat, according to standard protocol.
Active Comparator: Incubator-torso bag
Placement into a plastic bag inside incubator
While being placed into an incubator, infant will be placed into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket over the plastic bag and will receive a cloth hat. He/she will remain in the bag for one hour.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Axillary temperature 36.5-37.5 degrees Celsius
Time Frame: 1-72 hours
Temperature taken per axilla for 1 minute
1-72 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Seizure
Time Frame: Up to 4 weeks
Seizure activity diagnosed by medical doctor or nurse. No electroencephalogram will be done.
Up to 4 weeks
Pneumothorax
Time Frame: Up to 4 weeks
Either chest radiograph documentation or clinical deterioration consistent with air leak
Up to 4 weeks
Sepsis
Time Frame: Up to 4 weeks
Culture proven or culture negative clinically treated course consistent with sepsis
Up to 4 weeks
Death
Time Frame: Up to 4 weeks
Cardiorespiratory failure
Up to 4 weeks
Hyperthermia
Time Frame: Up to 4 weeks
Axillary temperature > 38 degrees Celsius per temperature taken per axilla for one minute
Up to 4 weeks
Blood glucose
Time Frame: Up to 4 weeks
Measure of blood glucose per laboratory value taken per heel stick
Up to 4 weeks
Weight gain
Time Frame: Up to 4 weeks
Infant will be weighed daily and rates of weight gain will be calculated
Up to 4 weeks
Major brain injury
Time Frame: Up to 4 weeks
Intracranial hemorrhage grade 3-4 or periventricular leukomalacia documented on cranial ultrasound
Up to 4 weeks
Pulmonary hemorrhage
Time Frame: Up to 4 weeks
Blood seen in the endotracheal tube and treated by physician
Up to 4 weeks
Blood Pressure
Time Frame: Up to 4 weeks
Measure of extremity blood pressure per cuff taken during nursery stay
Up to 4 weeks
Respiratory Distress Syndrome (RDS) Respiratory Distress Syndrome (RDS)
Time Frame: Up to 4 weeks
Documentation of increased work of breathing, retractions, and a need for oxygen, intubation, or surfactant
Up to 4 weeks
Bronchopulmonary dysplasia (BPD)
Time Frame: 28 days after birth
Oxygen requirement at 28 days after birth
28 days after birth
Necrotizing enterocolitis or intestinal perforation
Time Frame: Up to 4 weeks
Documentation of pneumatosis or intestinal perforation on x-ray or treatment course for clinical necrotizing enterocoliities per Bell's Classification stage greater than 1.
Up to 4 weeks
Length of time in Incubator
Time Frame: Up to 4 weeks
Documentation of length of time spent in incubator and number of times placed in incubator
Up to 4 weeks
Temperature and humidity
Time Frame: 1 hour
A recording of the air temperature and humidity within the incubator will be obtained with each axillary temperature measurement
1 hour

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

June 1, 2012

Primary Completion (Anticipated)

October 1, 2018

Study Completion (Anticipated)

October 1, 2019

Study Registration Dates

First Submitted

May 21, 2012

First Submitted That Met QC Criteria

May 21, 2012

First Posted (Estimate)

May 23, 2012

Study Record Updates

Last Update Posted (Actual)

February 20, 2019

Last Update Submitted That Met QC Criteria

February 18, 2019

Last Verified

February 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UAB Neo 008

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypothermia

Clinical Trials on Incubator-no plastic bag

3
Subscribe